PatCom Medical's Innovative Distal Chip Endoscope Receives FDA Approval

August 24, 2023 09:05 AM AEST | By EIN Presswire

Google News:

PatCom Medical's Innovative Distal Chip Endoscope Receives FDA Approval — Image source: EIN Presswire

Recent News

Northern Star and Evolution Mining Shares Tumble on ASX 200

Defence and Critical Minerals Stocks Signal Momentum on ASX 200 and Al...

Tech and Healthcare Drive Gains While Gold Stocks Weigh Down ASX 200

Marvell custom AI event: Here are Wall Street takeaways

BUFFALO, NEW YORK, UNITED STATES, August 23, 2023/EINPresswire.com/ -- PatCom Medical, a leading innovator in medical technology for SLPs and ENTs, is thrilled to announce that its groundbreaking Distal Chip Endoscope has received FDA approval. This approval marks a significant milestone in the field of endoscopy imaging and diagnostics, as the PatCom Distal Chip Endoscope looks to revolutionize the way clinicians assess and treat patients.

The PatCom Distal Chip Endoscope is the result of years of dedicated research and development by PatCom Medical's team. Unlike traditional endoscopes, which rely on bulky optical systems, the PatCom Distal Chip Endoscope employs HD, distal chip technology to capture high-definition images directly at the tip of the device. This design offers unprecedented image quality and clarity, while remaining cost-effective, allowing for more healthcare providers in a variety of settings to access HD imaging in their practices.

“The PatCom distal chip is first of its kind. For far too long, this image quality was only available to large hospitals with large funds. It is a game changer for all facilities and private practice owners, whether it is Speech Pathology or ENT,” comments Christoph Schmitz, CEO of PatCom Medical.

The benefits of the PatCom Distal Chip Endoscope are far-reaching. With its plug-and-play design, ergonomic handling, and small diameter, it keeps both the patient and the clinician in mind. Its streamlined design and small diameter allow for smoother navigation transnasally, helping to reducing patient discomfort. Furthermore, the enhanced image quality and ergonomic design can aid healthcare professionals in establishing and carrying out effective treatment strategies.

PatCom Medical is committed to ensuring the highest standards of patient care and product quality. The FDA's rigorous approval process included comprehensive evaluations of the device's safety, efficacy, and manufacturing processes.

“We are proud of this product and how it will assist SLPs and ENTs with patient care,” says Shelby Farwig, Director of Clinical Operations at PatCom Medical. “We believe this product puts ease of use and cost effectiveness on display while not compromising superb image quality.”

The launch of the PatCom Distal Chip Endoscope in the United States reaffirms PatCom Medical's position as an industry leader in medical innovation. The company remains dedicated to advancing medical technology to improve patient outcomes and enhance the capabilities of healthcare providers worldwide.

About PatCom Medical:
PatCom Medical is a pioneering medical technology company focused on improving human wellbeing by making established medical procedures more comfortable for patients and healthcare professionals. PatCom Medical was built on the foundation of improving patient comfort during procedures that access the pharynx, larynx, and esophagus.

For more information:
Website: https://patcommedical.com/distal-chip-endoscope/

Shelby Farwig-Director of Clinical Operations
PatCom Medical
[email protected]
Visit us on social media:
Facebook
LinkedIn
Instagram

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.